In vivo detection of monoaminergic degeneration in early parkinson disease by 18F-9-fluoropropyl-(1)-dihydrotetrabenzazine PET

Journal of Nuclear Medicine

Volumn 55, Issue 1, 2014, Pages 73-79

  Lin, Shao Cheng ^a   Lin, Kun Ju ^a,b   Hsiao, Ing Tsung ^b   Hsieh, Chia Ju ^b   Lin, Wey Yil ^a   Lu, Chin Song ^a,c   Wey, Shiaw Pyng ^a,b   Yen, Tzu Chen ^a   Kung, Mei Ping ^a,b,d   Weng, Yi Hsin ^a,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Parkinson's disease; VMAT2

Indexed keywords

9 FLUOROPROPYL DIHYDROTETRABENZAZINE F 18; ANTIPARKINSON AGENT; FLUORINE 18; TRACER; UNCLASSIFIED DRUG; 9 FLUOROETHYLDIHYDROTETRABENAZINE; 9-FLUOROETHYLDIHYDROTETRABENAZINE; AMINE; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SLC18A2 PROTEIN, HUMAN; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; AGED; AGING; ANTERIOR PUTAMEN; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; DRUG UPTAKE; EARLY DIAGNOSIS; FEMALE; HUMAN; IN VIVO STUDY; MALE; MODIFIED HOEHN AND YAHR STAGE; MONOAMINERGIC NERVE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NUCLEUS ACCUMBENS; OCCIPITAL CORTEX; PARKINSON DISEASE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTERIOR PUTAMEN; PREMOTOR CORTEX; PRIORITY JOURNAL; PUTAMEN; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPECIFIC UPTAKE RATIO; STANDARDIZATION; SUBSTANTIA NIGRA; SYMPTOM; UNIFIED PARKINSON DISEASE RATING SCALE; 18F-DTBZ PET; BRAIN; CASE CONTROL STUDY; CHEMISTRY; METABOLISM; MIDDLE AGED; SCINTISCANNING; TIME;

18F-DTBZ PET; PARKINSON'S DISEASE; VMAT2;

ADULT; AGED; AMINES; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TETRABENAZINE; TIME FACTORS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84894738679     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.121897     Document Type: Article

References (45)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5: 525-535.
2. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68: 384-386.
3. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318: 121-134.
4. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol. 1992;32: S125-S127.
5. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol. 1999;56: 33-39.
6. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci. 1991;18: 275-278.
7. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55: 181-184.
8. Kashmere J, Camicioli R, Martin W. Parkinsonian syndromes and differential diagnosis. Curr Opin Neurol. 2002;15: 461-466.
9. Brooks DJ. Assessment of Parkinson's disease by imaging. Parkinsonism Relat Disord. 2007;13: S268-S275.
10. Tsao HH, Lin KJ, Juang JH, et al. Binding characteristics of 9-fluoropropyl-(1)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Nucl Med Biol. 2010;37: 413-419.
11. Kilbourn MR. In vivo radiotracers for vesicular neurotransmitter transporters. Nucl Med Biol. 1997;24: 615-619.
12. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47: 493-503.
13. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain. 2011;134: 3290-3298.
14. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40: 873-884.
15. 11C] dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab. 1996;16: 1288-1299.
16. Martin WR, Wieler M, Stoessl AJ, et al. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol. 2008;63: 388-394.
17. Kung MP, Hou C, Goswami R, et al. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol. 2007;34: 239-246.
18. Goswami R, Ponde DE, Kung MP, et al. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006;33: 685-694.
19. 18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med. 2010;51: 1480-1485.
20. 18F-AV-133) summed uptake measurements. Nucl Med Biol. 2011;38: 1149-1155.
21. Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage. 1995;2: 89-101.
22. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15: 273-289.
23. 18F]AV-45 positron emission tomography in Chinese population. PLoS ONE. 2013;8: e58974.
24. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125: 861-870.
25. Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011;134: 3146-3166.
26. Shen LH, Liao MH, Tseng YC. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol. 2012;2012: 259-349.
27. Sioka C, Fotopoulos A, Kyritsis AP. Recent advances in PET imaging for evaluation of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2010;37: 1594-1603.
28. Stoessl AJ, Martin WRW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol. 2011;10: 987-1001.
29. 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med. 2004;45: 393-401.
30. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-Administration in the rat. J Neurosci. 1996;16: 3507-3510.
31. de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse. 2009;63: 713-716.
32. Sun J, Xu J, Cairns NJ, Perlmutter JS, Mach RH. Dopamine D1, D2, D3receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS ONE. 2012;7: e49483.
33. 18F-AV-133. J Nucl Med. 2010;51: 223-228.
34. Lu CS, Weng YH, Chen MC, et al. 99m Tc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med. 2004;45: 49-55.
35. Lin WY, Lin KJ, Weng YH, et al. Preliminary studies of differentia impairments of the dopaminergic system in subtypes of progressive supranuclear palsy. Nucl Med Commun. 2010;31: 974-980.
36. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114: 2283-2301.
37. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med. 1988;318: 876-880.
38. Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology. 2009;72: S12-S20.
39. Poletti M, Rosa AD, Bonuccelli U. Affective symptoms and cognitive functions in Parkinson's disease. J Neurol Sci. 2012;317: 97-102.
40. Rahman S, Griffin HJ, Quinn NP, et al. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord. 2008;23: 1428-1434.
41. Ballanger B, Poisson A, Broussolle E, Thobois S. Functional imaging of nonmotor signs in Parkinson's disease. J Neurol Sci. 2012;315: 9-14.
42. 18F]fluoro-L- dopa PET study. Brain. 2002;125: 1358-1365.
43. Remy P, Dorder M, Lees A, et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128: 1314-1322.
44. Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol Aging. 2012;33: 206.e29-39.
45. Brooks DJ, Piccini P. Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry. 2006;59: 908-918.